Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747043 · ClinicalTrials.gov registry record · Phase 3
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 256
- Enrollment target
NCT02747043 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 256 participants.
The verdict
NCT02747043, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 256 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of ABP 798 compared with rituximab in subjects with grade 1, 2, or 3a follicular B-cell NHL and low tumor burden. Subjects were randomized in a 1:1 ratio to receive a 375 mg/m\^2 intravenous infusion of either ABP 798 or rituximab once weekly for 4 weeks followed by dosing at weeks 12 and 20.
Interventions
- BIOLOGICAL Rituximab
- BIOLOGICAL ABP 798
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02747043
The ClinicalTrials.gov registry entry for NCT02747043 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT02747043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02747043 about?
NCT02747043 is a clinical study titled "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab". This was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of ABP 798 compared with rituximab in subjects with grade 1, 2, or 3a follicular B-cell NHL and low t...
What is the current status of trial NCT02747043?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 256 participants. The study started on 2016-05-25. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02747043?
The interventions under investigation include: Rituximab (BIOLOGICAL), ABP 798 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02747043?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.